BioCentury | May 12, 2020
Product Development

May 11 Quick Takes: Genfit’s elafibranor misses in NASH Phase III; plus AstraZeneca, Merck, Protalix and TolerogenixX

...KU-0059436, MK-7339) alpha galactosidase, pegunigalsidase alfa (CHF 6657; PRX-102) elafibranor (GFT505) AstraZeneca plc Merck & Co. Inc. Protalix BioTherapeutics Inc. Genfit S.A. Alpha galactosidase A Peroxisome...
BioCentury | Jul 18, 2019
Financial News

July 17 Financial Quick Takes: Chipscreen's Shanghai listing advances; plus Avrobio, Repligen and Seer

...other investors participated in the financing. Hongjiang Li, Staff Writer AVR-RD-01, avr-02 Avrobio Inc. Repligen Corp. Seer Inc. Shenzhen Chipscreen Biosciences Ltd. Alpha galactosidase A...
BioCentury | Jun 7, 2019
Company News

June 6 Company Quick Takes: Take two for Celgene's ozanimod; plus Protalix, ABPI, Axovant and Mylan

...treat Fabry disease in 1Q20. The candidate is a plant cell-expressed recombinant form of human alpha galactosidase A...
BioCentury | Oct 5, 2018
Clinical News

Vector copy number declines over time in four Fabry disease patients who received Avrobio gene therapy

...Fabry disease Endpoint: Safety, AGA enzyme activity Status: Phase I/II data Milestone: NA Chris Lieu AVR-RD-01, avr-02 Avrobio Inc. Alpha galactosidase A Fabry's...
BioCentury | Oct 1, 2018
Clinical News

Avrobio falls on data for Fabry gene therapy

...vector. Avrobio plans to use the improved vector in its Phase II trial. Chris Lieu AVR-RD-01, avr-02 Avrobio Inc. Alpha galactosidase A Fabry's...
BioCentury | Aug 13, 2018
Company News

Amicus prices Galafold at $315k per year

...five other countries. Amicus lost $1.04 to $14.31 on Monday. Alicia Parker Galafold, migalastat (AT1001, amigal) Amicus Therapeutics Inc. Alpha galactosidase A...
BioCentury | Aug 10, 2018
Company News

Amicus' Galafold wins accelerated approval from FDA

...prior to the approval, which Amicus announced after market hours. Paul Bonanos Galafold, migalastat (AT1001, amigal) Amicus Therapeutics Inc. Alpha galactosidase A...
BioCentury | Jun 22, 2018
Financial News

IPO roundup: Avrobio, Aptinyx, Magenta, Kezar, Xeris

...lead candidate AVR-RD-01 to treat Fabry's disease. The therapy comprises stem cells engineered to express alpha galactosidase A...
BioCentury | Jun 21, 2018
Financial News

Four companies in IPO quintet post first-day gains

...lead candidate AVR-RD-01 to treat Fabry's disease. The therapy comprises stem cells engineered to express alpha galactosidase A...
BioCentury | Jun 1, 2018
Financial News

Avrobio proposes $86.3M NASDAQ IPO

...slated to enter a Phase II trial mid-year -- comprises stem cells engineered to express alpha galactosidase A...
Items per page:
1 - 10 of 252